

IN THE CLAIMS:

Claims 1, 2, 7, 8, 10 and 14 are amended herein, claims 16 through 20 are canceled and new claims 21 to 24 are presented. All amendments and cancellations are made without prejudice or disclaimer and applicants may pursue such claims in related applications. Please note that all claims currently pending and under consideration in the referenced application are shown below. Please enter these claims as amended. This listing of claims will replace all prior versions and listings of claims in the application

1. (Currently Amended) A method for delivering genetic material to a target cell *in vitro*, comprising:
preparing a gene delivery vehicle comprising an expressible nucleic acid molecule encoding a recombinant gene of interest, a virus including a capsid or envelope surrounding said expressible nucleic acid molecule, and a first member of a specific binding pair, said first member of the specific binding pair expressed on an exterior of said capsid or envelope and said first member of the specific binding pair not being a viral antigen naturally expressed on said delivery vehicle;
coupling a bispecific conjugate to said first member of the specific binding pair to form a gene delivery vehicle complex, said bispecific conjugate comprising a second member of the specific binding pair covalently coupled to a targeting moiety, said targeting moiety capable of binding to a target molecule associated with a surface of the target cell; and
delivering said gene delivery vehicle complex to the target cell *in vitro*.
2. (Currently Amended) The method according to claim 1, wherein said first member of the specific binding pair ~~is configured without a~~ has no specific affinity for said target molecule associated with the surface of the target cell.
3. (Original) The method according to claim 1, wherein said first member of the specific binding pair is recombinantly expressed by said gene delivery vehicle.

4. (Original) The method according to claim 1, wherein said first member of the specific binding pair comprises an immunoglobulin binding moiety.

5. (Original) The method according to claim 4, wherein said first member of the specific binding pair is configured to have binding specificity to a constant region of an immunoglobulin.

6. (Original) The method according to claim 5, wherein said second member of the specific binding pair comprises an immunoglobulin.

7. (Currently Amended) The method according to claim 1, wherein said capsid or envelope is ~~configured to be~~ incapable of binding to the target cell.

8. (Currently Amended) A kit of parts for delivering genetic material to a target cell, comprising:

a gene delivery vehicle, said gene delivery vehicle comprising an expressible nucleic acid molecule encoding a recombinant gene of interest, a virus including a capsid or envelope surrounding said expressible nucleic acid molecule, and a first member of a specific binding pair;

said first member of the specific binding pair expressed on an exterior of said capsid or envelope and said first member of the specific binding pair not being a viral antigen naturally expressed on said delivery vehicle; and

a bispecific conjugate ~~configured~~ for coupling to said first member of the specific binding pair, said bispecific conjugate comprising a second member of the specific binding pair covalently coupled to a targeting moiety, said targeting moiety capable of binding to a target molecule associated with a surface of the target cell.

9. (Original) The kit of parts according to claim 8, wherein said first member of the specific binding pair comprises an immunoglobulin binding moiety.

10. (Currently Amended) The kit of parts according to claim 9, wherein said immunoglobulin binding moiety is ~~configured for~~ capable of binding to a constant region of an immunoglobulin.

11. (Original) The kit of parts according to claim 10, wherein said immunoglobulin binding moiety comprises a moiety selected from the group consisting of protein A, protein G, and a Fc receptor.

12. (Original) The kit of parts according to claim 8, wherein said second member of the specific binding pair comprises an immunoglobulin.

13. (Original) The kit of parts according to claim 8, wherein said targeting moiety comprises an antibody or a fragment or a derivative thereof.

14. (Currently Amended) The kit of parts according to claim 8, wherein said virus is derived from a virus selected from the group consisting of adenoviruses, adeno-associated viruses, and retroviruses by altering the capsid or envelope of said virus.

15. (Original) The kit of parts according to claim 8, wherein said target molecule is receptor for which said targeting moiety is a ligand.

Claims 16 through 20 (canceled).

21. (New) The kit of parts according to claim 8, wherein said first member of the specific binding pair has no specific affinity for said target molecule associated with the surface of the target cell.

22. (New) The kit of parts according to claim 8, wherein said capsid or envelope is incapable of binding to the target cell.

23. (New) The kit of parts according to claim 8, wherein said first member of the specific binding pair is recombinantly expressed by said gene delivery vehicle.

24. (New) The kit of parts according to claim 8, comprising a multitude of different bispecific conjugates, comprising the same second member of the specific binding pair but a number of different targeting moieties.